PUBLIC RECORD / FREQUENTLY ASKED
CJC-1295, answered from the record.
Twenty-two questions about safety, the DAC distinction, dosing, and regulatory standing — answered the way the dossier answers everything: plainly, and cited.
Frequently asked questions about CJC-1295
These answers summarize the published CJC-1295 record. Each begins with a direct answer and cites a study where it makes a quantitative claim. Nothing here is medical advice or a dosing recommendation; CJC-1295 is an unapproved research chemical [8].
What is CJC-1295?
A synthetic analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions [2]. The DAC variant is covalently bound to serum albumin for a multi-day half-life; the no-DAC form ("Modified GRF 1-29") is short-acting. It is an unapproved research chemical.
What does CJC-1295 do?
It is a long-acting GHRH analog: it binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1. In healthy men a single dose raised mean GH about 46% and IGF-1 about 45% a week later [3].
Is CJC-1295 safe?
There is no adequate long-term human safety data; CJC-1295 is unapproved for human use [8]. Documented and theoretical concerns include fluid retention from GH-driven sodium retention [9], a cancer-risk signal tied to sustained IGF-1 elevation [8], and immunogenicity flagged by the FDA [8]. It is handled as a research chemical.
Are CJC-1295 peptides safe?
No long-term human safety data establish this. The published human record is limited to short early-phase PK studies [1][3]; sustained GH/IGF-1 elevation carries theoretical risks, the FDA has cited immunogenicity [8], and the original DAC development program was discontinued [7].
Does CJC-1295 affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the androgen axis; the published studies measured GH and IGF-1, not testosterone [3]. There is no controlled human evidence that it raises or lowers testosterone.
Does CJC-1295 lower testosterone?
No controlled human study shows CJC-1295 lowering testosterone; it acts on the GH/IGF-1 axis rather than the gonadal axis, and the published trials did not track testosterone as an endpoint [3].
Does CJC-1295 raise testosterone?
No. CJC-1295 stimulates growth-hormone release through the GHRH receptor [3]; testosterone was not an endpoint in the published human studies, and there is no controlled evidence that it raises testosterone.
Is CJC-1295 a steroid?
No. It is a peptide — a synthetic GHRH analog that acts upstream on the pituitary to release the body's own growth hormone [3]. It is not an anabolic-androgenic steroid and does not act on androgen receptors.
What are the side effects of CJC-1295?
Reported and theoretical concerns center on GH-axis stimulation: fluid retention and edema, because GH increases renal sodium reabsorption [9]; effects on insulin sensitivity and substrate metabolism [6]; and, from sustained IGF-1 elevation, the cancer-risk signal seen in IGF-1 epidemiology [8]. The FDA has also flagged immunogenicity [8].
What to expect when taking CJC-1295?
The measured physiology in studies is elevated GH and IGF-1 — mean GH about 46% and IGF-1 about 45% a week after a single dose in healthy men [3]. Beyond those biomarkers, controlled long-term outcome data do not exist, so claims about body composition or anti-aging outrun the evidence.
Why does the FDA cite immunogenicity as a concern for CJC-1295?
FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee listed immunogenicity among the safety concerns for GH secretagogues including CJC-1295 — synthetic peptides can provoke anti-drug antibodies, and the analog lacks the characterization an approved drug would have. CJC-1295 was reviewed and not recommended for the 503A compounding bulks list [8].
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator and is handled as a research chemical. At the 2024 FDA Pharmacy Compounding Advisory Committee it was reviewed and not recommended for the 503A compounding bulks list, with immunogenicity cited among the concerns [8].
How much CJC-1295 should I take?
Published human PK studies used single subcutaneous doses of 30, 60, or 90 ug/kg [1][3]. These describe research dosing, not a human recommendation; CJC-1295 has no approved human use, and circulating fixed-microgram protocols are not from controlled trials.
How much CJC-1295 DAC should I take?
The DAC variant's multi-day half-life (5.8-8.1 days) was studied at 30-90 ug/kg single subcutaneous doses [1][3]; murine work showed once-daily 2 ug normalized growth [4]. Online fixed-microgram protocols are not derived from controlled human trials.
What is CJC-1295 with DAC?
The version carrying a maleimidopropionyl-lysine handle that covalently bonds to a thiol on circulating serum albumin, forming a peptide-albumin conjugate that extends the plasma half-life toward that of albumin [2] — hence a multi-day duration of action.
What is CJC-1295 DAC?
"DAC" = Drug Affinity Complex, the albumin-conjugation chemistry. In rats the conjugate gave about 4-fold higher GH AUC than unconjugated hGRF(1-29) and was detectable in plasma beyond 72 hours [2], the design that makes CJC-1295 long-acting.
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so studied routes are subcutaneous (primary) and intravenous [1]. This describes laboratory handling, not human-use instructions.
Where to inject CJC-1295?
The route used across the published studies is subcutaneous injection, with intravenous used in early GRF(1-29) PK work [1][3]. This reflects research methodology; CJC-1295 has no approved human administration.
How much CJC-1295 / ipamorelin should I take?
There is no validated human dose for the combination. Community protocols pair fixed microgram amounts of each, but these are not derived from controlled human trials; the published rationale is only the mechanism-level point that a GHRH analog and a GHRP act on different receptors [3].
Does CJC-1295 and ipamorelin work?
At the mechanism level a GHRH analog and a GHRP act through distinct receptors, which is why the pairing is discussed for additive GH release. But the published human data are on the acute GH/IGF-1 response [1][3], not on long-term body-composition outcomes of the specific combination in healthy adults.
What is CJC-1295 ipamorelin?
A research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin). Because the two act on different receptors, the combination is discussed as a way to layer GH stimulation [3] — a mechanistic rationale, not an outcome proven in controlled human trials.
Are peptides safer than TRT?
Not an answerable equivalence: testosterone-replacement therapy is an approved, monitored treatment with extensive data, whereas CJC-1295 is an unapproved research chemical with only short early-phase human PK data [1][3]. The closest approved GHRH-analog comparator is tesamorelin, studied in HIV-associated fat accumulation [10].